Helus Pharma, a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference, scheduled for September 14-16, 2026, in New York City, provides a platform for the company to discuss its progress with investors and industry peers. The fireside chat is set to be webcast live on September 14 at 9 a.m. EDT, with a replay available on the company's investor relations website.
This announcement comes at a critical time for Helus Pharma, which is advancing its lead candidate, HLP003, in Phase 3 clinical trials for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status that expedites development and review of drugs intended to treat serious conditions with preliminary clinical evidence indicating substantial improvement over existing therapies. Additionally, the company is developing HLP004, a proprietary NSA in Phase 2 trials for generalized anxiety disorder, and maintains an extensive research portfolio of investigational compounds.
The company's focus on serotonergic agonists represents a novel approach to treating mental health conditions by targeting serotonin pathways believed to promote neuroplasticity, the brain's ability to reorganize itself by forming new neural connections. This mechanism aims to provide durable improvements in mental health, potentially addressing the large unmet need for patients who do not respond adequately to current treatments. According to the World Health Organization, depression is a leading cause of disability worldwide, and anxiety disorders are among the most common mental health conditions, highlighting the importance of developing effective therapies.
Helus Pharma's participation in the H.C. Wainwright conference is significant as it offers the company an opportunity to engage with the investment community, potentially attracting capital to support its clinical development programs. The company, which operates in Canada, the United States, the United Kingdom, and Ireland, has made strides in the mental health space, and its progress in clinical trials could position it as a key player in the evolving landscape of psychiatric treatments.
The conference also comes amid growing interest in psychedelic-inspired therapies and novel mechanisms for mental health. While traditional antidepressants like SSRIs are widely used, they often have limitations, including delayed onset of action and side effects. Helus Pharma's NSAs are designed to activate serotonin pathways more directly, potentially offering faster and more sustained relief. If successful, these therapies could transform the standard of care for millions of patients worldwide.
Investors and stakeholders can access the live webcast and replay through the Events & Presentations page on Helus Pharma's website, where they can also find additional corporate updates. The company's newsroom, available at https://ibn.fm/HELP, provides the latest news and developments regarding its progress.
As Helus Pharma continues to advance its pipeline, the outcome of its Phase 3 trial for HLP003 will be a key milestone to watch. The FDA's Breakthrough Therapy Designation underscores the potential of this candidate to address a serious condition, and positive results could lead to regulatory submission and eventual market approval. Similarly, the Phase 2 data for HLP004 in generalized anxiety disorder will be important in determining its future development.
The company's commitment to innovation in mental health is reflected in its extensive research portfolio and its global operations. With a focus on developing therapies that could provide durable improvements, Helus Pharma aims to meet the needs of individuals suffering from depression, anxiety, and other mental health conditions. The H.C. Wainwright conference provides a platform for the company to communicate its vision and progress to a broader audience, potentially influencing the direction of mental health treatment development.
